Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 3.794
Filter
1.
Addict Biol ; 29(5): e13400, 2024 May.
Article in English | MEDLINE | ID: mdl-38706091

ABSTRACT

Substance use disorders are characterized by inhibition deficits related to disrupted connectivity in white matter pathways, leading via interaction to difficulties in resisting substance use. By combining neuroimaging with smartphone-based ecological momentary assessment (EMA), we questioned how biomarkers moderate inhibition deficits to predict use. Thus, we aimed to assess white matter integrity interaction with everyday inhibition deficits and related resting-state network connectivity to identify multi-dimensional predictors of substance use. Thirty-eight patients treated for alcohol, cannabis or tobacco use disorder completed 1 week of EMA to report substance use five times and complete Stroop inhibition testing twice daily. Before EMA tracking, participants underwent resting state functional MRI and diffusion tensor imaging (DTI) scanning. Regression analyses were conducted between mean Stroop performances and whole-brain fractional anisotropy (FA) in white matter. Moderation testing was conducted between mean FA within significant clusters as moderator and the link between momentary Stroop performance and use as outcome. Predictions between FA and resting-state connectivity strength in known inhibition-related networks were assessed using mixed modelling. Higher FA values in the anterior corpus callosum and bilateral anterior corona radiata predicted higher mean Stroop performance during the EMA week and stronger functional connectivity in occipital-frontal-cerebellar regions. Integrity in these regions moderated the link between inhibitory control and substance use, whereby stronger inhibition was predictive of the lowest probability of use for the highest FA values. In conclusion, compromised white matter structural integrity in anterior brain systems appears to underlie impairment in inhibitory control functional networks and compromised ability to refrain from substance use.


Subject(s)
Diffusion Tensor Imaging , Inhibition, Psychological , Magnetic Resonance Imaging , White Matter , Humans , White Matter/diagnostic imaging , White Matter/pathology , Male , Female , Adult , Ecological Momentary Assessment , Substance-Related Disorders/physiopathology , Substance-Related Disorders/diagnostic imaging , Stroop Test , Alcoholism/physiopathology , Alcoholism/diagnostic imaging , Brain/diagnostic imaging , Brain/physiopathology , Middle Aged , Tobacco Use Disorder/physiopathology , Tobacco Use Disorder/diagnostic imaging , Marijuana Abuse/physiopathology , Marijuana Abuse/diagnostic imaging , Corpus Callosum/diagnostic imaging , Corpus Callosum/pathology , Smartphone , Neural Pathways/diagnostic imaging , Neural Pathways/physiopathology , Anisotropy , Young Adult
2.
Rev Colomb Psiquiatr (Engl Ed) ; 53(1): 93-102, 2024.
Article in English, Spanish | MEDLINE | ID: mdl-38677941

ABSTRACT

INTRODUCTION: The co-occurrence of substance use disorder with at least one other mental disorder is called dual pathology, which in turn is characterised by heterogeneous symptoms that are difficult to diagnose and have a poor response to treatment. For this reason, the identification and validation of biomarkers is necessary. Within this group, possible electroencephalographic biomarkers have been reported to be useful in diagnosis, treatment and follow-up, both in neuropsychiatric conditions and in substance use disorders. This article aims to review the existing literature on electroencephalographic biomarkers in dual pathology. METHODS: A narrative review of the literature. A bibliographic search was performed on the PubMed, Science Direct, OVID, BIREME and Scielo databases, with the keywords: electrophysiological biomarker and substance use disorder, electrophysiological biomarker and mental disorders, biomarker and dual pathology, biomarker and substance use disorder, electroencephalography, and substance use disorder or comorbid mental disorder. RESULTS: Given the greater amount of literature found in relation to electroencephalography as a biomarker of mental illness and substance use disorders, and the few articles found on dual pathology, the evidence is organised as a biomarker in psychiatry for the diagnosis and prediction of risk and as a biomarker for dual pathology. CONCLUSIONS: Although the evidence is not conclusive, it suggests the existence of a subset of sites and mechanisms where the effects of psychoactive substances and the neurobiology of some mental disorders could overlap or interact.


Subject(s)
Biomarkers , Electroencephalography , Mental Disorders , Substance-Related Disorders , Humans , Electroencephalography/methods , Biomarkers/metabolism , Mental Disorders/physiopathology , Mental Disorders/diagnosis , Substance-Related Disorders/diagnosis , Substance-Related Disorders/physiopathology , Diagnosis, Dual (Psychiatry)
3.
Front Neuroendocrinol ; 73: 101121, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38253240

ABSTRACT

Early life stress (ELS) is defined as an acute or chronic stressor that negatively impacts a child's development. ELS is associated with substance use and mental health problems. This narrative literature review focuses on sex and gender differences in the effects of ELS on 1) adolescent neuroendocrine development; 2) pubertal brain maturation; and 3) development of internalizing symptoms and subsequent substance use. We posit that ELS may generate larger hormonal dysregulation in females than males during puberty, increasing internalizing symptoms and substance use. Future research should consider sex and gender differences in neuroendocrine developmental processes when studying the link between ELS and negative health outcomes.


Subject(s)
Neurosecretory Systems , Sex Characteristics , Stress, Psychological , Substance-Related Disorders , Humans , Substance-Related Disorders/physiopathology , Adolescent , Neurosecretory Systems/metabolism , Male , Female , Stress, Psychological/metabolism , Stress, Psychological/physiopathology , Adverse Childhood Experiences , Adolescent Development/physiology
4.
Drug Alcohol Depend ; 250: 110917, 2023 09 01.
Article in English | MEDLINE | ID: mdl-37579623

ABSTRACT

BACKGROUND: Humans often administer psychostimulants in party or music festival settings characterized by warm ambient temperatures, which may impact drug effects; however, preclinical studies rarely investigate drug effects at multiple ambient temperatures. Work with 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) suggests that the presence of a 3,4-methylenedioxy ring moiety may influence ambient temperature-dependent effects. METHODS: Locomotor activity and conditioned place preference dose-response curves were generated at 20±2°C for two amphetamine analogues (MDMA and methamphetamine [METH]) and two cathinone analogues (MDPV and α-pyrrolidinopentiophenone [αPVP]) in mice. Effects were then redetermined at 29±2°C for each drug and assay. RESULTS: All four drugs elicited dose-dependent locomotor stimulation at the cool ambient temperature. At the warm ambient temperature, MDMA and MDPV produced sensitization to stereotypy, whereas METH and αPVP produced sensitization to locomotor activity. Regarding place conditioning, the warm ambient environment potentiated place preference elicited by doses of METH and αPVP that were sub-threshold in the cool ambient environment, but attenuated the effects of analogous doses of MDMA and MDPV. CONCLUSIONS: These studies suggest that warmer ambient temperatures may potentiate typical stimulant effects for the drugs lacking the 3,4-methylenedioxy ring, but may potentiate the behaviorally toxic/adverse effects for the drugs containing a 3,4-methylenedioxy ring. Thus, preclinical abuse liability studies conducted at standard laboratory temperatures may not fully capture the effects of psychostimulants and highlight the need to model the environments in which drugs are typically used by humans.


Subject(s)
Central Nervous System Stimulants , Conditioning, Operant , Locomotion , N-Methyl-3,4-methylenedioxyamphetamine , Synthetic Cathinone , Temperature , Animals , Male , Mice , Central Nervous System Stimulants/adverse effects , Conditioning, Operant/drug effects , Conditioning, Operant/physiology , Dose-Response Relationship, Drug , Hallucinogens/adverse effects , Locomotion/drug effects , Locomotion/physiology , N-Methyl-3,4-methylenedioxyamphetamine/adverse effects , Substance-Related Disorders/physiopathology , Synthetic Cathinone/adverse effects , Disease Models, Animal
6.
Med Sci Monit ; 28: e934996, 2022 Mar 11.
Article in English | MEDLINE | ID: mdl-35273137

ABSTRACT

BACKGROUND The purpose of this study was to compare pain symptoms in drug rehabilitees with or without human immunodeficiency virus (HIV) in Yunnan Province, China. MATERIAL AND METHODS This was a retrospective single-center cohort study. A total of 120 male substance users, including 65 with HIV, were enrolled after admission to the Fifth Drug Rehabilitation Center in Yunnan Province. Individuals who were >18 years of age and who had illicit drugs detected in their urine, despite not having used drugs for at least 2 months, were included. The patients evaluated their average pain intensity for the previous 4 weeks using a visual analog scale. PainDETECT questionnaire scores were used to classify pain into nociceptive and mixed component subgroups. Sleep quality was also evaluated using the Pittsburgh Sleep Quality Index scale. RESULTS The prevalence and intensity of the pain symptoms were higher for the drug rehabilitees with HIV than for those without HIV. Moreover, the rehabilitees with HIV were more likely to experience neuropathic and nociceptive pain, whereas those without HIV reported only nociceptive pain. The sleep quality of the rehabilitees with HIV was also lower, regardless of the pain symptoms. CONCLUSIONS Our results showed that the drug rehabilitees with HIV in Yunnan Province, China, experienced more frequent and stronger pain (both nociceptive and neuropathic) than those without HIV. They also experienced poorer sleep quality, although it was unrelated to pain. Our results provide data to support clinical diagnosis and treatment.


Subject(s)
HIV Infections/psychology , Pain Measurement/psychology , Substance-Related Disorders/psychology , Adult , China , HIV Infections/physiopathology , HIV Infections/virology , Humans , Male , Middle Aged , Nociceptive Pain/physiopathology , Nociceptive Pain/psychology , Nociceptive Pain/rehabilitation , Retrospective Studies , Sleep , Substance Abuse Treatment Centers/statistics & numerical data , Substance-Related Disorders/physiopathology , Substance-Related Disorders/rehabilitation , Surveys and Questionnaires , Young Adult
7.
PLoS One ; 17(2): e0263442, 2022.
Article in English | MEDLINE | ID: mdl-35192667

ABSTRACT

BACKGROUND: Emerging health professionals in undergraduate programs should be equipped to provide care to people with substance use disorder (SUD). The students' personal attributes may impact their attitude toward those with SUD. This study aims to evaluate the impact of personal attributes of Jordanian undergraduate health students on their attitudes toward SUD and examine the relationship between the personal attributes and their devaluation and discriminatory (stigmatory) behaviour toward those with SUD. METHOD: A cross-sectional descriptive design was used to examine the attitudes and stigmatory behaviours. The data were collected between May to October 2017 with a structured questionnaire that consisted of three parts: 1) a data sheet to collect the socio-demographic characteristics of the participants, 2) the Acute Mental Health Scale (ATAMHS), and 3) the Devaluation-Discrimination Scale (DDS). FINDINGS: Younger and females demonstrated a positive attitude toward those with SUD compared to older or male students. Age, gender, and previous experience with SUD are significant factors that affect their attitude. CONCLUSION: Identifying the attitude to people with SUD and personal attributes of emerging health professionals in Jordan will help identify the need to educate them prior to their entry into practice.


Subject(s)
Attitude of Health Personnel , Social Discrimination/psychology , Social Stigma , Students/psychology , Substance-Related Disorders/psychology , Cross-Sectional Studies , Education, Medical, Undergraduate , Female , Humans , Jordan , Male , Substance-Related Disorders/physiopathology , Surveys and Questionnaires , Young Adult
8.
Addict Biol ; 27(1): e12958, 2022 01.
Article in English | MEDLINE | ID: mdl-32783345

ABSTRACT

Much research seeks to articulate the brain structures and pathways implicated in addiction and addiction recovery. Prominent neurobiological models emphasize the interplay between cortical and limbic brain regions as a main driver of addictive processes, but largely do not take into consideration sensory and visceral information streams that link context and state to the brain and behavior. Yet these brain-body information streams would seem to be necessary elements of a comprehensive model of addiction. As a starting point, we describe the overlap between one current model of addiction circuitry and the neural network that not only regulates cardiovascular system activity but also receives feedback from peripheral cardiovascular processes through the baroreflex loop. We highlight the need for neurobiological, molecular, and behavioral studies of neural and peripheral cardiovascular signal integration during the experience of internal states and environmental contexts that drive alcohol and other drug use behaviors. We end with a call for systematic, mechanistic research on the promising, yet largely unexamined benefits to addiction treatment of neuroscience-informed, adjunctive interventions that target the malleability of the cardiovascular system to alter brain processes.


Subject(s)
Cardiovascular System/physiopathology , Substance-Related Disorders/physiopathology , Humans , Neurobiology , Sensation/physiology
9.
Int J Obes (Lond) ; 46(1): 107-112, 2022 01.
Article in English | MEDLINE | ID: mdl-34508153

ABSTRACT

BACKGROUND/OBJECTIVES: While an increased risk for substance use disorders (SUD) and also for several adverse pregnancy and birth outcomes in patients who have undergone bariatric surgery have been well documented when considered separately, an association between these important risk factors has not been investigated. This study explored the potential dependence of these two bariatric surgery-related risks. SUBJECTS/METHODS: This study was a retrospective cohort study with adult women (18-45) who underwent bariatric surgery between 1996 and 2016 and who gave birth after surgery between 1996 and 2018. The study population consisted of 1849 post-bariatric surgery women with 3010 reported post-surgical births. Subjects with post-surgical, prenatal SUD were identified based on diagnosis codes extracted within the 10 months prior to delivery. Using random-effects logistic regression with retrospective cohort data, preterm birth, low birth weight, macrosomia, Caesarian delivery, congenital anomalies, and neonatal intensive care unit admission were considered as outcomes. RESULTS: About 10% (n = 289) of women had an SUD diagnosis within 10 months prior to child delivery. Women with SUD during pregnancy had significantly more pregnancy and birth complications compared to women without SUD: preterm birth (OR = 2.08, p = 0.03, 95% CI: 1.07-4.03), low birth weight (OR = 3.41, p < 0.01, 95% CI: 1.99-5.84), Caesarian delivery (OR = 9.71, p < 0.01, 95% CI: 2.69-35.05), and neonatal intensive care unit admission (OR = 3.87, p < 0.01, 95% CI: 2.04-7.34). Women with SUD had lower risk for macrosomia than women without SUD (OR = 0.07, p = 0.02, 95% CI: 0.01-0.70). CONCLUSION: Results from this study demonstrated that post-bariatric surgery women who had SUD during pregnancy had significantly more pregnancy- and birth-related complications than post-surgery pregnant women without SUD, despite the reduction in macrosomia. Where possible, greater prenatal surveillance of post-surgery women with SUD should be considered.


Subject(s)
Prenatal Care/statistics & numerical data , Substance-Related Disorders/complications , Adult , Bariatric Surgery/methods , Bariatric Surgery/statistics & numerical data , Cohort Studies , Female , Humans , Infant, Newborn , Pregnancy , Pregnancy Complications/epidemiology , Pregnancy Outcome/epidemiology , Prenatal Care/methods , Retrospective Studies , Substance-Related Disorders/physiopathology , Utah/epidemiology
10.
Addict Biol ; 27(1): e13063, 2022 01.
Article in English | MEDLINE | ID: mdl-34101312

ABSTRACT

Patients with attention-deficit/hyperactivity disorder (ADHD) are often diagnosed with comorbid substance misuse (SM), which is associated with poor treatment efficacy. Although literature indicates similar inhibitory control deficits in both conditions, it is unclear whether SM in ADHD exaggerates pre-existing deficits, with additive or distinct impairments in patients. Our aim was to examine SM effects on inhibitory control in ADHD. Behavioural and functional magnetic resonance imaging (fMRI) data from a stop-signal task were compared across ADHD patients with and without SM (ADHD + SM and ADHD-only, respectively) and controls (n = 33/group; 79 males, mean age 18.02 ± 2.45). To limit substance use disorder (SUD) trait effects, groups were matched for parental SUD. Overall, we found worse performance for ADHD-only and/or ADHD + SM compared with controls but no difference between the ADHD groups. Moreover, the ADHD groups showed decreased frontostriatal and frontoparietal activity during successful and failed stop trials. There were no differences between the ADHD groups in superior frontal nodes, but there was more decreased activation in temporal/parietal nodes in ADHD-only compared with ADHD + SM. During go-trials, ADHD + SM showed decreased activation in inferior frontal nodes compared with ADHD-only and controls. Findings during response inhibition showed deficits in inhibition and attentional processes for ADHD patients with and without SM. Despite no evidence for SM effects during response inhibition, results during go-trials suggest distinct effects on nodes that are associated with several executive functions. Future studies should investigate whether distinct deficits in ADHD + SM relate to poor treatment results and can direct development of distinct ADHD treatment strategies for these patients.


Subject(s)
Attention Deficit Disorder with Hyperactivity/physiopathology , Inhibition, Psychological , Substance-Related Disorders/physiopathology , Adolescent , Adult , Attention , Brain/physiopathology , Brain Mapping , Executive Function , Female , Humans , Magnetic Resonance Imaging , Male , Netherlands , Neuropsychological Tests , Young Adult
11.
Int J Mol Sci ; 22(23)2021 Nov 30.
Article in English | MEDLINE | ID: mdl-34884757

ABSTRACT

Nociceptin/orphanin FQ (N/OFQ) is a 17-residue neuropeptide that binds the nociceptin opioid-like receptor (NOP). N/OFQ exhibits nucleotidic and aminoacidics sequence homology with the precursors of other opioid neuropeptides but it does not activate either MOP, KOP or DOP receptors. Furthermore, opioid neuropeptides do not activate the NOP receptor. Generally, activation of N/OFQ system exerts anti-opioids effects, for instance toward opioid-induced reward and analgesia. The NOP receptor is widely expressed throughout the brain, whereas N/OFQ localization is confined to brain nuclei that are involved in stress response such as amygdala, BNST and hypothalamus. Decades of studies have delineated the biological role of this system demonstrating its involvement in significant physiological processes such as pain, learning and memory, anxiety, depression, feeding, drug and alcohol dependence. This review discusses the role of this peptidergic system in the modulation of stress and stress-associated psychiatric disorders in particular drug addiction, mood, anxiety and food-related associated-disorders. Emerging preclinical evidence suggests that both NOP agonists and antagonists may represent a effective therapeutic approaches for substances use disorder. Moreover, the current literature suggests that NOP antagonists can be useful to treat depression and feeding-related diseases, such as obesity and binge eating behavior, whereas the activation of NOP receptor by agonists could be a promising tool for anxiety.


Subject(s)
Opioid Peptides/physiology , Receptors, Opioid/physiology , Stress, Physiological/physiology , Animals , Anxiety Disorders/drug therapy , Anxiety Disorders/physiopathology , Brain/drug effects , Brain/physiopathology , Feeding and Eating Disorders/drug therapy , Feeding and Eating Disorders/physiopathology , Humans , Models, Neurological , Mood Disorders/drug therapy , Mood Disorders/physiopathology , Opioid Peptides/agonists , Opioid Peptides/antagonists & inhibitors , Reward , Stress, Physiological/drug effects , Substance-Related Disorders/drug therapy , Substance-Related Disorders/physiopathology , Nociceptin Receptor , Nociceptin
12.
Rev. andal. med. deporte ; 14(4): 238-241, 2021-12-10. tab
Article in Portuguese | IBECS | ID: ibc-227735

ABSTRACT

Objetivo: Verificar as barreiras que influenciam a não realização de atividade física no tempo livre entre usuários de substâncias psicoativas.Método: 144 indivíduos com média de idade de 44.3±12.6 anos foram entrevistados respondendo um questionário que verifica as barreiras para a prática de atividades físicas. Foi aplicado o teste Qui-quadrado de independência aceitando um p<0.05 como significativo.Resultados: Os dados mostraram que há associação entre as sentenças do questionário e o padrão de resposta dos indivíduos [x2(13)=193.88; p≤0.001]. Foi encontrada significância como barreira para prática de atividade física o cansaço físico, falta de companhia, falta de incentivo familiar e acometimento de dores leves ou mal-estar. Por outro lado, a falta de tempo, fator climático, não disponibilidade no ambiente, não disponibilidade de equipamento e falta de habilidade física foram apontados, significativamente, como não serem barreiras para a prática de atividade física em usuários de substâncias psicoativas.Conclusão: A partir destes dados será possível estabelecer estratégias mais efetivas para a promoção da prática de atividade física nesta população. (AU)


Objetivo: Verificar las barreras que influyen en los usuarios de sustancias psicoactivas para no utilizar su tiempo libre para practicar actividad física.Método: 144 personas, con edad de 44.3 ± 12.6 años, respondieron a un cuestionario sobre las barreras para la practica de actividad física. Se aplicó el test de independencia de chi-cuadrado, aceptando como significativa um valor de p<0.05.Resultados: Los datos muestran que existe asociación entre las sentencias del cuestionario y el patrón de respuesta de los individuos [x2(13)=193.88; p≤0.001]. Se consideró significativa la existencia de barreras para la práctica de actividad física como el cansancio físico, la falta de un compañero y motivación familiar, padecimiento de dolores o malestar ligeros. Por otro lado, la falta de tiempo, el factor climático, la indisponibilidad en el medio ambiente, la falta de equipos y de entrenamiento físico no fueron señalados de manera significativa como barreras para la práctica de actividad física en usuarios de sustancias psicoactivas.Conclusión: En base a estos datos, será posible establecer estrategias más efectivas para promover la práctica de actividad física en esta población. (AU)


Objective: To verify the barriers that influence the non-performance of physical activity in free time among users of psychoactive substances.Methods: 144 individuals with a mean age of 44.3±12.6 years were interviewed by answering a questionnaire that checks the barriers to physical activity. The Chi-square test of independence was applied accepting a p<0.05 as significant.Results: The data showed that there is an association between the sentences of the questionnaire and the response pattern of individuals [x2(13)=193.88; p≤0.001]. Significance was found as a barrier to physical activity the physical tiredness, lack of company, lack of family incentive and involvement of mild pain or discomfort. On the other hand, lack of time, climatic factor, non-availability in the environment, non-availability of equipment, and lack of physical ability were significantly pointed out as not being barriers to the practice of physical activity in users of psychoactive substances.Conclusion: From these data it will be possible to establish more effective strategies for the promotion of physical activity in this population. (AU)


Subject(s)
Humans , Male , Female , Young Adult , Adult , Substance-Related Disorders/prevention & control , Substance-Related Disorders/physiopathology , Mental Health Services , Exercise/psychology , Motor Activity , Surveys and Questionnaires
13.
Regul Toxicol Pharmacol ; 127: 105053, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34619288

ABSTRACT

Lemborexant is a dual orexin receptor antagonist (DORA) approved in multiple countries including the United States, Japan, Canada and Australia for the treatment of adults with insomnia. As required for marketing approval of new compounds with central nervous system activity with sedating effects, the abuse potential of lemborexant was assessed in accordance with regulatory guidelines, which included three nonclinical studies. These assessments comprised physical dependence and drug discrimination studies in rats and a self-administration study in rhesus monkeys. There was no evidence of withdrawal signs following abrupt drug discontinuation, indicating that lemborexant does not induce physical dependence. In the drug discrimination study, lemborexant at doses up to 1000 mg/kg administered orally did not cross-generalize to the zolpidem training stimulus, although another DORA included in the same experiment, suvorexant, showed partial generalization with zolpidem. In rhesus monkeys, lemborexant treatment did not induce any gross behavioral changes, and there was no increase in self-administration rates compared with control, indicative of a lack of reinforcing effects of lemborexant. Collectively, these nonclinical studies support the position that lemborexant, which has been placed in Schedule IV by the United States Drug Enforcement Administration, has a low risk of abuse in humans.


Subject(s)
Hypnotics and Sedatives/pharmacology , Orexin Receptor Antagonists/pharmacology , Pyridines/pharmacology , Pyrimidines/pharmacology , Substance-Related Disorders/physiopathology , Animals , Dose-Response Relationship, Drug , Female , Hypnotics and Sedatives/pharmacokinetics , Male , Orexin Receptor Antagonists/pharmacokinetics , Pyridines/pharmacokinetics , Pyrimidines/pharmacokinetics , Rats , Substance Withdrawal Syndrome/physiopathology
14.
Int Rev Neurobiol ; 160: 175-221, 2021.
Article in English | MEDLINE | ID: mdl-34696873

ABSTRACT

Adolescence is a transitional period between childhood and adulthood, in which the individual undergoes significant cognitive, behavioral, physical, emotional, and social developmental changes. During this period, adolescents engage in experimentation and risky behaviors such as licit and illicit drug use. Adolescents' high vulnerability to abuse drugs and natural reinforcers leads to greater risk for developing substance use disorders (SUDs) during adulthood. Accumulating evidence indicates that the use and abuse of licit and illicit drugs during adolescence and emerging adulthood can disrupt the cholinergic system and its processes. This review will focus on the effects of peri-adolescent nicotine and/or alcohol use, or exposure, on the cholinergic system during adulthood from preclinical and clinical studies. This review further explores potential cholinergic agents and pharmacological manipulations to counteract peri-adolescent nicotine and/or alcohol abuse.


Subject(s)
Cholinergic Agents , Substance-Related Disorders , Adolescent , Cholinergic Agents/pharmacology , Humans , Substance-Related Disorders/drug therapy , Substance-Related Disorders/physiopathology
15.
Neuropharmacology ; 198: 108769, 2021 10 15.
Article in English | MEDLINE | ID: mdl-34481834

ABSTRACT

The circuitry of addiction comprises several neural networks including the midbrain - an expansive region critically involved in the control of motivated behaviors. Midbrain nuclei like the Edinger-Westphal (EW) and dorsal raphe (DR) contain unique populations of neurons that synthesize many understudied neuroactive molecules and are encircled by the periaqueductal gray (PAG). Despite the proximity of these special neuron classes to the ventral midbrain complex and surrounding PAG, functions of the EW and DR remain substantially underinvestigated by comparison. Spanning approximately -3.0 to -5.2 mm posterior from bregma in the mouse, these various cell groups form a continuum of neurons that we refer to collectively as the subaqueductal paramedian zone. Defining how these pathways modulate affective behavioral states presents a difficult, yet conquerable challenge for today's technological advances in neuroscience. In this review, we cover the known contributions of different neuronal subtypes of the subaqueductal paramedian zone. We catalogue these cell types based on their spatial, molecular, connectivity, and functional properties and integrate this information with the existing data on the EW and DR in addiction. We next discuss evidence that links the EW and DR anatomically and functionally, highlighting the potential contributions of an EW-DR circuit to addiction-related behaviors. Overall, we aim to derive an integrated framework that emphasizes the contributions of EW and DR nuclei to addictive states and describes how these cell groups function in individuals suffering from substance use disorders. This article is part of the special Issue on 'Neurocircuitry Modulating Drug and Alcohol Abuse'.


Subject(s)
Gray Matter/physiology , Nerve Net/physiology , Neuropeptides/physiology , Periaqueductal Gray/physiology , Raphe Nuclei/physiology , Animals , Gray Matter/physiopathology , Humans , Nerve Net/physiopathology , Periaqueductal Gray/physiopathology , Raphe Nuclei/physiopathology , Substance-Related Disorders/physiopathology
16.
PLoS One ; 16(9): e0248794, 2021.
Article in English | MEDLINE | ID: mdl-34506492

ABSTRACT

Electroencephalography (EEG) likely reflects activity of cortical neurocircuits, making it an insightful estimation for mental health in patients with substance use disorder (SUD). EEG signals are recorded as sinusoidal waves, containing spectral amplitudes across several frequency bands with high spatio-temporal resolution. Prior work on EEG signal analysis has been made mainly at individual electrodes. These signals can be evaluated from advanced aspects, including sub-regional and hemispheric analyses. Due to limitation of computational techniques, few studies in earlier work could conduct data analyses from these aspects. Therefore, EEG in patients with SUD is not fully understood. In the present retrospective study, spectral powers from a data house containing opioid (OUD), methamphetamine/stimulants (MUD), and alcohol use disorder (AUD) were extracted, and then converted into five distinct topographic data (i.e., electrode-based, cortical subregion-based, left-right hemispheric, anterior-posterior based, and total cortex-based analyses). We found that data conversion and reorganization in the topographic way had an impact on EEG spectral powers in patients with OUD significantly different from those with MUD or AUD. Differential changes were observed from multiple perspectives, including individual electrodes, subregions, hemispheres, anterior-posterior cortices, and across the cortex as a whole. Understanding the differential changes in EEG signals may be useful for future work with machine learning and artificial intelligence (AI), not only for diagnostic but also for prognostic purposes in patients with SUD.


Subject(s)
Brain/diagnostic imaging , Electroencephalography/methods , Substance-Related Disorders/diagnostic imaging , Adult , Alcoholism/diagnostic imaging , Alcoholism/physiopathology , Female , Humans , Male , Methamphetamine , Middle Aged , Opioid-Related Disorders/diagnostic imaging , Opioid-Related Disorders/physiopathology , Retrospective Studies , Substance-Related Disorders/physiopathology
17.
Neuropharmacology ; 198: 108763, 2021 10 15.
Article in English | MEDLINE | ID: mdl-34433088

ABSTRACT

Between 2005 and 2009, several research groups identified a strikingly dense inhibitory input to midbrain dopamine neurons arising from a previously uncharted region posterior to the ventral tegmental area (VTA). This region is now denoted as either the rostromedial tegmental nucleus (RMTg) or the "tail of the VTA" (tVTA), and is recognized to express distinct genetic markers, encode negative "prediction errors" (inverse to dopamine neurons), and play critical roles in behavioral inhibition and punishment learning. RMTg neurons are also influenced by many categories of abused drugs, and may drive some aversive responses to such drugs, particularly cocaine and alcohol. However, despite much progress, many important questions remain about RMTg molecular/genetic properties, diversity of projection targets, and applications to addiction, depression, and other neuropsychiatric disorders. This article is part of the special Issue on 'Neurocircuitry Modulating Drug and Alcohol Abuse'.


Subject(s)
Behavior, Animal/physiology , Behavior/physiology , Dopamine/physiology , Ventral Tegmental Area/physiology , Animals , Dopaminergic Neurons/physiology , Humans , Substance-Related Disorders/physiopathology , Substance-Related Disorders/psychology , Tegmentum Mesencephali/drug effects , Ventral Tegmental Area/physiopathology
18.
Addict Biol ; 26(6): e13079, 2021 11.
Article in English | MEDLINE | ID: mdl-34374475

ABSTRACT

Stimulant use disorder is associated with significant global health burden. Despite evidence for sex differences in the development and maintenance of stimulant use disorder, few studies have focused on mechanisms underpinning distinct trajectories in females versus males, including the effect of the ovarian sex hormones estrogen and progesterone. This review aimed to identify and synthesise the existing preclinical and clinical literature on the effect of ovarian sex hormones on stimulant consumption in females. A systematic search of peer-reviewed literature identified 1593 articles, screened using the following inclusion criteria: (1) adult female humans or animals, (2) using stimulant drugs, (3) ovarian sex hormones were administered exogenously OR were measured in a validated manner and (4) with stimulant consumption as an outcome measure. A total of 50 studies (3 clinical and 47 preclinical) met inclusion criteria. High-estrogen (low progesterone) phases of the menstrual/estrus cycle were associated with increased stimulant use in preclinical studies, while there were no clinical studies examining estrogen and stimulant consumption. Consistent preclinical evidence supported progesterone use reducing stimulant consumption, which was also identified in one clinical study. The review was limited by inconsistent data reporting across studies and different protocols across preclinical laboratory paradigms. Importantly, almost all studies examined cocaine use, with impact on methamphetamine use a significant gap in the existing evidence. Given the safety and tolerability profile of progesterone, further research is urgently needed to address this gap, to explore the potential therapeutic utility of progesterone as a treatment for stimulant use disorder.


Subject(s)
Central Nervous System Stimulants/administration & dosage , Estrogens/physiology , Gonadal Steroid Hormones/physiology , Progestins/physiology , Substance-Related Disorders/physiopathology , Animals , Dose-Response Relationship, Drug , Estrogens/pharmacology , Female , Humans , Menstrual Cycle/physiology , Progestins/pharmacology , Substance-Related Disorders/psychology
19.
Neurobiol Dis ; 158: 105473, 2021 10.
Article in English | MEDLINE | ID: mdl-34371144

ABSTRACT

CalDAG-GEFI (CDGI) is a protein highly enriched in the striatum, particularly in the principal spiny projection neurons (SPNs). CDGI is strongly down-regulated in two hyperkinetic conditions related to striatal dysfunction: Huntington's disease and levodopa-induced dyskinesia in Parkinson's disease. We demonstrate that genetic deletion of CDGI in mice disrupts dendritic, but not somatic, M1 muscarinic receptors (M1Rs) signaling in indirect pathway SPNs. Loss of CDGI reduced temporal integration of excitatory postsynaptic potentials at dendritic glutamatergic synapses and impaired the induction of activity-dependent long-term potentiation. CDGI deletion selectively increased psychostimulant-induced repetitive behaviors, disrupted sequence learning, and eliminated M1R blockade of cocaine self-administration. These findings place CDGI as a major, but previously unrecognized, mediator of cholinergic signaling in the striatum. The effects of CDGI deletion on the self-administration of drugs of abuse and its marked alterations in hyperkinetic extrapyramidal disorders highlight CDGI's therapeutic potential.


Subject(s)
Dendrites , Guanine Nucleotide Exchange Factors/genetics , Neostriatum/physiopathology , Neuronal Plasticity , Parasympathetic Nervous System/physiopathology , Synapses , Animals , Basal Ganglia Diseases/genetics , Basal Ganglia Diseases/physiopathology , Basal Ganglia Diseases/psychology , Central Nervous System Stimulants/pharmacology , Excitatory Postsynaptic Potentials/genetics , Hyperkinesis/genetics , Hyperkinesis/psychology , Long-Term Potentiation , Male , Mice , Mice, Knockout , Motor Activity , Polymorphism, Single Nucleotide , Receptor, Muscarinic M1/genetics , Receptor, Muscarinic M1/physiology , Substance-Related Disorders/genetics , Substance-Related Disorders/physiopathology , Substance-Related Disorders/psychology
20.
Neuropharmacology ; 198: 108766, 2021 10 15.
Article in English | MEDLINE | ID: mdl-34454912

ABSTRACT

The coronavirus disease 2019 (Covid-19) pandemic intensified the already catastrophic drug overdose and substance use disorder (SUD) epidemic, signaling a syndemic as social isolation, economic and mental health distress, and disrupted treatment services disproportionally impacted this vulnerable population. Along with these social and societal factors, biological factors triggered by intense stress intertwined with incumbent overactivity of the immune system and the resulting inflammatory outcomes may impact the functional status of the central nervous system (CNS). We review the literature concerning SARS-CoV2 infiltration and infection in the CNS and the prospects of synergy between stress, inflammation, and kynurenine pathway function during illness and recovery from Covid-19. Taken together, inflammation and neuroimmune signaling, a consequence of Covid-19 infection, may dysregulate critical pathways and underlie maladaptive changes in the CNS, to exacerbate the development of neuropsychiatric symptoms and in the vulnerability to develop SUD. This article is part of the special Issue on 'Vulnerabilities to Substance Abuse'.


Subject(s)
COVID-19/epidemiology , Drug Misuse/statistics & numerical data , SARS-CoV-2 , Substance-Related Disorders/epidemiology , Adaptation, Psychological , Angiotensin-Converting Enzyme 2/physiology , Animals , Axons/virology , COVID-19/immunology , COVID-19/physiopathology , COVID-19/psychology , Comorbidity , Disease Susceptibility , Endothelial Cells/virology , Humans , Immunity, Innate , Inflammation/etiology , Kynurenine/metabolism , Neurons/virology , Neurotransmitter Agents/metabolism , Olfactory Mucosa/virology , Pandemics , SARS-CoV-2/physiology , Social Isolation , Stress, Psychological , Substance-Related Disorders/etiology , Substance-Related Disorders/physiopathology , Tryptophan/metabolism , Viral Tropism
SELECTION OF CITATIONS
SEARCH DETAIL
...